Antidiabetic therapy in post kidney transplantation diabetes mellitus
Introduction
In the last decade increased emphasis on the integrated management of care for patients with type 2 diabetes was followed by steady improvements in self-management behaviours and risk-factor control. In combination with the adoption of new, effective pharmacological approaches, these strategies were associated with large reductions in the rates of acute myocardial infarction, stroke, amputation, and end-stage renal disease among adults with diabetes between 1990 and 2010 [1]. Moreover, patients with diabetes have experienced a disproportionate reduction in in-hospital mortality and a complete reversal in risk of mortality relative to patients without diabetes [2]. Severe hypoglycaemia, however, is still the most common adverse effect of glucose-lowering therapies and associates with poor outcomes especially in vulnerable patients with multiple comorbidities [3]. Hospital admission rates for hypoglycaemia among older patients have now even surpassed hospitalisations for hyperglycaemia [4]. Thus, the efforts to improve metabolic control in patients with diabetes – although generally successful – have still been linked with unacceptably high rates of hypoglycaemia. New pharmacologic strategies including incretin-based therapies as a component of multimodal individualised diabetes management might help to increase the safety of lowering glucose.
PTDM has previously been suggested to be just a form of type 2 diabetes [5], [6]. However, although PTDM is not mentioned in the American Diabetes Association (ADA) position statement [7], it most reasonably classifies in the category of “other specific types” of diabetes mellitus rather than in the type 2 diabetes category. According to the ADA experts, it is less important to label the particular type of diabetes than to understand the pathogenesis of hyperglycaemia in order to treat it effectively. We have previously pointed out that hyperglycaemia after kidney transplantation appears rapidly, and that the appearance of overt PTDM is steeper in kidney transplant patients than the development of type 2 diabetes in the general population [8], [9], due to a variety of transplant-specific mechanisms [10]. Adding to this pathomechanistic difference, evidence generated by us and others suggests that β cell dysfunction rather than insulin resistance is the principal factor contributing to PTDM development [11], [12], [13], [14], [15], mainly as a consequence of calcineurin inhibitor action on β cells [16], [17], [18], [19], [20]. Previous consensus guidelines have emphasised the individualisation of immunosuppressive therapy as a hallmark of PTDM management [6]. However, a large international group of clinicians and scientists most recently recommended using strategies for prevention and treatment of PTDM beyond modification of immunosuppression [21]. Therefore, we here aim at reviewing and discussing pharmacological antihyperglycaemic therapy after kidney transplantation.
Our review focusses on antidiabetic substances for which at least some evidence regarding their use in PTDM is available or for which – at least theoretically – a positive impact on PTDM can be expected. This holds true for insulin, incretin-based therapies (in particular DPP-4 inhibitors), glitazones and metformin, as will be discussed below. From our point of view there is little rationale for the use of sulfonylureas and glinides in PTDM patients because of the negative cardiovascular profile of at least some of these compounds in the non-transplanted population [22]. In addition sulfonylureas failed to produce a sustained antihyperglycaemic effect in type 2 diabetes and appear to have a negative impact on β cell function, being particularly undesirable in the context of PTDM [23]. α-Glucosidase inhibitors show limited glucose-lowering efficacy in general combined with high rates of gastrointestinal side-effects making their use in transplant recipients less attractive [24]. Furthermore, their use in CKD stages 3 and higher is not recommended [25]. SGLT2 inhibitors will also not be discussed here, due to the lack of available data in kidney transplant recipients.
Section snippets
Insulin
Insulin treatment in patients with type 2 diabetes is typically introduced late during disease development [26], and this strategy has previously also been advocated for patients after renal transplantation in the previous PTDM consensus guidelines dating back to 2003 [6]. However, there are several potential advantages for earlier insulin administration in type 2 diabetes [27], most importantly protection of β cells by aggressive lowering of hyperglycaemia. An intermittent insulin therapy of
Incretin-based therapies
The first incretin was identified in the 1970s and was given the name glucose-dependent insulinotropic peptide (GIP) followed by the discovery of the even more potent incretin Glucagon-like peptide-1 (GLP-1) 1in the 1980s [37]. Among the plethora of physiologic reactions to GLP-1 are increased insulin biosynthesis and β cell proliferation with decreased glucagon secretion, delayed gastric emptying, and an increase in insulin sensitivity in muscle cells along with appetite down-regulation (Fig. 3
Metformin
Chemically, metformin belongs to the group of biguanides that are derived from the plant Galega officinalis (French lilac). Metformin has been in clinical use since the late 1950s although approval by the Food and Drug Administration (FDA) was granted as late as 1994. It is now the most widely prescribed antidiabetic drug in the world serving as first-line agent in patients with type 2 diabetes mellitus who did not reach their HbA1c target with life-style modifications alone [98], [99].
Glitazones
Glitazones or thiazolidinediones including rosiglitazone and pioglitazone can be used in patients with glomerular filtration rates below 30 ml/min. They act via modulation of the peroxisome proliferator-activated receptor γ (PPAR- γ) thereby improving glucose metabolism by acting as insulin sensitisers [118]. PPAR-γ activation increases insulin sensitivity in several tissues including muscle, fat and liver and leads to reduced levels of free fatty acids. In type 2 diabetes mellitus glitazones
Conclusion
Improving long-term outcomes of kidney transplantation is the major challenge of transplantation medicine today and reducing the rate of cardiovascular events in this particularly vulnerable population represents a major goal. PTDM is an important contributor to mortality in kidney transplanted patients, and effective management of this comorbidity could therefore lead to a profound improvement in long-term outcomes after kidney transplantation. Although evidence from prospective trials for the
References (135)
- et al.
Diabetes mellitus after kidney transplantation in the United States
Am J Transplant
(2003) - et al.
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients
Am J Transplant
(2003) - et al.
Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions
Am J Transplant
(2014) - et al.
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Lancet Diabetes Endocrinol
(2015) - et al.
Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial
Lancet
(2008) - et al.
Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus
J Ren Nutr
(2009) Hypoglycemia associated with renal failure
Endocrinol Metab Clin North Am
(1989)- et al.
Glucagon-like peptide-1 7-36: a physiological incretin in man
Lancet
(1987) - et al.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Lancet
(2006) The biology of incretin hormones
Cell Metab
(2006)
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial
Am J Kidney Dis
Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes
Biochem Biophys Res Commun
Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial
Lancet
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Gastroenterology
Patient survival after renal transplantation: IV. Impact of post-transplant diabetes
Kidney Int
The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events
Kidney Int
Cardiovascular effects of DPP-4 inhibition: beyond GLP-1
Vasc Pharmacol
Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines
Biochem Biophys Res Commun
Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
Nutr Metab Cardiovasc Dis
Dipeptidyl peptidase in autoimmune pathophysiology
Adv Clin Chem
Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation–a randomized, double-blind, placebo-controlled trial
Am J Transplant
Changes in diabetes-related complications in the United States, 1990-2010
N Engl J Med
Decade-Long Trends in Mortality Among Patients With and Without Diabetes Mellitus at a Major Academic Medical Center
JAMA Intern Med
National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations
JAMA Intern Med
National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011
JAMA Intern Med
New-Onset Diabetes After Kidney Transplantation: Prevalence, Risk Factors, and Management
Transplantation
New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003
Transplantation
Diagnosis and classification of diabetes mellitus
Diabetes Care
Novel views on new-onset diabetes after transplantation: development, prevention and treatment
Nephrol Dial Transplant
A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients
Nephrol Dial Transplant
beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus
Transplantation
[Improvement of insulin sensitivity after renal transplantation measured by a glucose clamp technique] - Abstract published in English
J Nippon Med Sch
Glucose Metabolism After Renal Transplantation
Diabetes Care
Pancreatic beta-Cell Dysfunction and Risk of New-Onset Diabetes After Kidney Transplantation
Diabetes Care
Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells
J Clin Invest
Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506
Transplantation
Evaluating mechanisms of post-transplant diabetes mellitus
Nephrol Dial Transplant
Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study
J Am Soc Nephrol
Mechanism of the diabetogenic action of cyclosporin A
Horm Metab Res
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
N Engl J Med
Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review
Ann Intern Med
Management of drugs affecting blood glucose in diabetic patients with renal failure
Diabetes Metab
Glycemic response to newly initiated diabetes therapies
Am J Manag Care
Early insulin treatment in type 2 diabetes: what are the pros?
Diabetes Care
Early Basal insulin therapy decreases new-onset diabetes after renal transplantation
J Am Soc Nephrol
Metformin and other antidiabetic agents in renal failure patients
Kidney Int
Impact of end-stage renal disease and dialysis on glycemic control
Semin Dial
New-onset diabetes mellitus after kidney transplantation in Denmark
Clin J Am Soc Nephrol
Can new-onset diabetes after kidney transplant be prevented?
Diabetes Care
Comment on: Chakkera et al. Can new-onset diabetes after kidney transplant be prevented?
Diabetes Care
Cited by (10)
Long-term efficacy and safety of anti-hyperglycaemic agents in new-onset diabetes after transplant: Results from outpatient-based 1-year follow-up and a brief review of treatment options
2021, Diabetes and Metabolic Syndrome: Clinical Research and ReviewsCitation Excerpt :However, recent studies have also generated the hypothesis that antidiabetic treatment in PTDM patients might not halt cardiovascular events in long run [5]. Management of Type 2 diabetes mellitus (T2DM) is more challenging after transplant than in non-transplant settings because of greater risk of fluctuating kidney function, variations in insulin resistance, altered immunosuppression, intermittent episodes of rejection, and drug-drug interactions [6]. Evidence suggests that probably beta-cell dysfunction rather than insulin resistance is the main contributing factor for NODAT development with early insulin-based correction of postoperative hyperglycemia perhaps having a beta-cell protective effect [7,8].
Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
2021, Transplant InternationalThe Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients
2020, Transplantation DirectEmpagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety
2019, American Journal of Transplantation